Star Alliance

Star Alliance Biotech is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on the development of innovative biologics for cardiovascular and cerebrovascular diseases. The company's lead candidate, SND01 (recombinant human pro-urokinase), is a potent thrombolytic agent currently in Phase 3 clinical trials for acute myocardial infarction and Phase 2 for ischemic stroke. Star Alliance Biotech leverages its proprietary high-efficiency protein expression and purification platforms to produce high-purity therapeutic proteins with optimized safety and efficacy profiles. Backed by leading venture capital firms such as Legend Capital and SDIC Fund Management, the company aims to address critical unmet needs in the treatment of acute thrombotic conditions.